Abstract
Journal of Bone and Mineral Research, Journal of Bone and Mineral Research June 2005:20:962-970 (doi: 10.1359/JBMR.050105)

Full Text Printable PDF (154.055 KB)

Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With Osteoporosis

Peiqi Chen, 1   Julie H Satterwhite, 1   Angelo A Licata, 2   E Michael Lewiecki, 3   Adrien A Sipos, 1   Derek M Misurski, 1   Rachel B Wagman1  

1Eli Lilly and Company, Indianapolis, Indiana, USA;

2Department of Endocrinology, Diabetes, and Metabolism, The Cleveland Clinic, Cleveland, Ohio, USA;

3New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico, USA.

Address reprint requests to: Rachel B Wagman, MD Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285, USA E-mail:




The relationship between early changes in biochemical markers of bone turnover and the subsequent BMD response to daily teriparatide therapy in women with postmenopausal osteoporosis was studied. Changes in five biochemical markers, obtained from a subset of women enrolled in the Fracture Prevention Trial, were examined. Early increases in the PICP and the PINP were the best predictors of BMD response to teriparatide in this analysis.

Introduction: Early reductions in biochemical markers of bone turnover with antiresorptive therapy negatively correlate with subsequent increases in BMD. We undertook this analysis to determine if early changes in biochemical markers with teriparatide therapy predict subsequent increases in BMD.

Materials and Methods: In the Fracture Prevention Trial, 1637 postmenopausal women with osteoporosis were randomized to receive daily, self-administered, subcutaneous injections of placebo, teriparatide 20 μg/day, or teriparatide 40 μg/day. Serum concentrations of two bone formation markers (bone-specific alkaline phosphatase [bone ALP] and the carboxy-terminal extension peptide of procollagen type 1 [PICP]) and urinary concentrations of two bone resorption markers (free deoxypyridinoline [DPD] and N-terminal telopeptide [NTX]) were assessed in a trial population subset (n = 520) at baseline and at 1, 3, 6, and 12 months. We also assessed serum concentrations of another bone formation marker, the amino-terminal extension peptide of procollagen type 1 (PINP), in a subset of 771 women at baseline and 3 months. Lumbar spine (LS) BMD was measured by DXA at baseline and 18 months. Femoral neck BMD was measured at baseline and 12 months.

Results and Conclusion: Baseline bone turnover status correlated positively and significantly with BMD response. The highest correlations occurred for the LS BMD response to teriparatide 20 μg/day. Among all studied biochemical markers, increases in PICP at 1 month and PINP at 3 months correlated best with increases in LS BMD at 18 months (0.65 and 0.61, respectively; p < 0.05). The relationships between these two biochemical markers and the LS BMD response were stronger than the corresponding relationships for the femoral neck BMD response. Using receiver operator curve analysis, we determined that the increases in PICP at 1 month and PINP at 3 months were the most sensitive and accurate predictors of the LS BMD response.

Cited by

Nelson B Watts, Paul D Miller, Lynn A Kohlmeier, Anthony Sebba, Peiqi Chen, Mayme Wong and Kelly Krohn. (2009) Vertebral Fracture Risk Is Reduced in Women Who Lose Femoral Neck BMD With Teriparatide Treatment. Journal of Bone and Mineral Research 24:6, 1125-1131
Online publication date: 1-Jun-2009.
Abstract | Full Text | Printable PDF (748 KB) 
Mary L Bouxsein and Pierre D Delmas. (2008) Considerations for Development of Surrogate Endpoints for Antifracture Efficacy of New Treatments in Osteoporosis: A Perspective. Journal of Bone and Mineral Research 23:8, 1155-1167
Online publication date: 1-Aug-2008.
Abstract | Full Text | Printable PDF (261 KB) 
Pawel Szulc and Pierre D Delmas. (2008) Chapter 34.Biochemical Markers of Bone Turnover in Osteoporosis. Primer 7:1, 174-179
Online publication date: 1-Jan-2008.
Citation | Full Text | Printable PDF (748 KB) 
Felicia Cosman and Susan Greenspan. (2008) Chapter 51.Parathyroid Hormone Treatment for Osteoporosis. Primer 7:1, 244-249
Online publication date: 1-Jan-2008.
Citation | Full Text | Printable PDF (86 KB) 
Peiqi Chen, Paul D Miller, Robert Recker, Heinrich Resch, Asad Rana, Imre Pavo and Adrien A Sipos. (2007) Increases in BMD Correlate With Improvements in Bone Microarchitecture With Teriparatide Treatment in Postmenopausal Women With Osteoporosis*. Journal of Bone and Mineral Research 22:8, 1173-1180
Online publication date: 1-Aug-2007.
Abstract | Full Text | Printable PDF (1913 KB) 
Peiqi Chen, Christopher P Jerome, David B Burr, Charles H Turner, Yanfei L Ma, Asad Rana and Masahiko Sato. (2007) Interrelationships Between Bone Microarchitecture and Strength in Ovariectomized Monkeys Treated With Teriparatide*. Journal of Bone and Mineral Research 22:6, 841-848
Online publication date: 1-Jun-2007.
Abstract | Full Text | Printable PDF (2349 KB) 
Xin Chen, In-Hwan Song, James E Dennis and Edward M Greenfield. (2007) Endogenous PKIγ Limits the Duration of the Anti-Apoptotic Effects of PTH and β-Adrenergic Agonists in Osteoblasts. Journal of Bone and Mineral Research 22:5, 656-664
Online publication date: 1-May-2007.
Abstract | Full Text | Printable PDF (3543 KB) 
Peiqi Chen, Paul D Miller, Pierre D Delmas, Derek A Misurski and John H Krege. (2006) Change in Lumbar Spine BMD and Vertebral Fracture Risk Reduction in Teriparatide-Treated Postmenopausal Women With Osteoporosis*. Journal of Bone and Mineral Research 21:11, 1785-1790
Online publication date: 1-Nov-2006.
Abstract | Full Text | Printable PDF (2756 KB) 
Robert Lindsay, Felicia Cosman, Hua Zhou, Mathias P Bostrom, Victor W Shen, JoAnn D Cruz, Jeri W Nieves and David W Dempster. (2006) A Novel Tetracycline Labeling Schedule for Longitudinal Evaluation of the Short-Term Effects of Anabolic Therapy With a Single Iliac Crest Bone Biopsy: Early Actions of Teriparatide. Journal of Bone and Mineral Research 21:3, 366-373
Online publication date: 1-Mar-2006.
Abstract | Full Text | Printable PDF (658 KB) 
Armen H Tashjian Jr and Robert F Gagel. (2006) Teriparatide [Human PTH(1-34)]: 2.5 Years of Experience on the Use and Safety of the Drug for the Treatment of Osteoporosis. Journal of Bone and Mineral Research 21:3, 388-365
Online publication date: 1-Mar-2006.
Citation | Full Text | Printable PDF (502 KB) 

 

Prev. Article | Next Article
View Printable PDF (154 KB)
Add to favorites
Email to a friend
TOC Alert | Citation Alert What is RSS?

 
 
Quick Search
for 
Authors:
Peiqi Chen,
Julie H Satterwhite,
Angelo A Licata,
E Michael Lewiecki,
Adrien A Sipos,
Derek M Misurski,
Rachel B Wagman
Keywords:
osteoporosis
teriparatide
biochemical markers of bone turnover
BMD
clinical trials